Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: pritumumab | 0.81 |
| trials ClinicalTrials.gov | 20 Parkinson's trials, 1 stopped | 0.96 |
| literature PubMed | 380 Parkinson's papers of 6,863 | 0.22 |
| pathways Reactome | 10 pathways; mostly lysosome and autophagy | 1.00 |
No case: the score is under the bar. Receipt 4992
Sealed predictions
- VIM in dopamine neurons, braak-0.36 (p 0.341) → +0.47 (p 0.197)receipt 4999
Swarm cases
receipt 4999: VIM in dopamine neurons, braak
- power
- full sample +0.19 (p 0.444, n 18), 95% CI -0.30 to +0.60. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.25 (p 0.315, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.26 (p 0.306, n 18). could be the mix.
- skeptic
- leave-one-out range +0.08 to +0.28, sign flips 0; without severely affected donors +0.19 (p 0.444, n 18). fragile.
- cell type
- strongest in astrocytes: -0.61 (p 0.0072, n 18) vs +0.19 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VIM in dopamine neurons.
case closed: every proposal failed a challenge.
Receipts
loading the receipts